112 related articles for article (PubMed ID: 12028037)
1. The endogenous granulocyte colony-stimulating factor response following autologous peripheral blood stem cell transplantation is impaired in patients with myeloma.
Morris TC; Magill MK; Drake M; Price S; Ranaghan L; Bridget S; Jordan AE; Irvine AE
Br J Haematol; 2002 Jun; 117(3):646-9. PubMed ID: 12028037
[TBL] [Abstract][Full Text] [Related]
2. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of hemopoietic recovery after peripheral blood stem cell transplantation: impact of stem cell purification and G-CSF.
Piccirillo N; Sorà F; Laurenti L; Chiusolo P; Serafini R; Cicconi S; Leone G; Sica S
Am J Hematol; 2002 Jan; 69(1):7-14. PubMed ID: 11835324
[TBL] [Abstract][Full Text] [Related]
5. Comparison of autografting using mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas.
Brice P; Divine M; Marolleau JP; Haioun C; Dalcortivo L; Sitthy X; Beaujean F; Norol F; Benbunan M; Reyes F
Bone Marrow Transplant; 1994 Jul; 14(1):51-5. PubMed ID: 7524907
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation.
Shimazaki C; Uchiyama H; Fujita N; Araki S; Sudo Y; Yamagata N; Ashihara E; Goto H; Inaba T; Haruyama H
Exp Hematol; 1995 Dec; 23(14):1497-502. PubMed ID: 8542937
[TBL] [Abstract][Full Text] [Related]
7. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
8. G-CSF administration favours SDF-1 release and activation of neutrophils and monocytes in recipients of autologous peripheral blood progenitor cells.
Gębura K; Butrym A; Chaszczewska-Markowska M; Wróbel T; Kuliczkowski K; Bogunia-Kubik K
Cytokine; 2019 Apr; 116():38-47. PubMed ID: 30685602
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
10. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation.
Cetkovský P; Koza V; Jindra P; Skopek P; Svojgrová M
Bone Marrow Transplant; 1997 Oct; 20(8):639-41. PubMed ID: 9383226
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
Bishop MR; Tarantolo SR; Geller RB; Lynch JC; Bierman PJ; Pavletic ZS; Vose JM; Kruse S; Dix SP; Morris ME; Armitage JO; Kessinger A
Blood; 2000 Jul; 96(1):80-5. PubMed ID: 10891434
[TBL] [Abstract][Full Text] [Related]
13. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
14. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Cortelazzo S; Viero P; Bellavita P; Rossi A; Buelli M; Borleri GM; Marziali S; Bassan R; Comotti B; Rambaldi A
J Clin Oncol; 1995 Apr; 13(4):935-41. PubMed ID: 7535843
[TBL] [Abstract][Full Text] [Related]
16. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony-stimulating factor mobilized whole blood containing over 0.3 x 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non-Hodgkin's lymphoma.
Jonkhoff AR; De Kreuk AM; Franschman G; Van Der Lelie J; Schuurhuis GJ; Dräger AM; Zweegman S; Huijgens PC; Ossenkoppele GJ
Br J Haematol; 2002 Jul; 118(1):90-100. PubMed ID: 12100131
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery.
Testa U; Martucci R; Rutella S; Scambia G; Sica S; Benedetti Panici P; Pierelli L; Menichella G; Leone G; Mancuso S
Blood; 1994 Nov; 84(10):3532-9. PubMed ID: 7949108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
